254 related articles for article (PubMed ID: 16377285)
1. Comparative safety of atorvastatin 80 mg versus 10 mg derived from analysis of 49 completed trials in 14,236 patients.
Newman C; Tsai J; Szarek M; Luo D; Gibson E
Am J Cardiol; 2006 Jan; 97(1):61-7. PubMed ID: 16377285
[TBL] [Abstract][Full Text] [Related]
2. Safety of atorvastatin derived from analysis of 44 completed trials in 9,416 patients.
Newman CB; Palmer G; Silbershatz H; Szarek M
Am J Cardiol; 2003 Sep; 92(6):670-6. PubMed ID: 12972104
[TBL] [Abstract][Full Text] [Related]
3. Tolerability of atorvastatin in a population aged > or =65 years: a retrospective pooled analysis of results from fifty randomized clinical trials.
Hey-Hadavi JH; Kuntze E; Luo D; Silverman P; Pittman D; Lepetri B
Am J Geriatr Pharmacother; 2006 Jun; 4(2):112-22. PubMed ID: 16860258
[TBL] [Abstract][Full Text] [Related]
4. Atorvastatin: a safety and tolerability profile.
Arca M
Drugs; 2007; 67 Suppl 1():63-9. PubMed ID: 17910522
[TBL] [Abstract][Full Text] [Related]
5. The safety and tolerability of atorvastatin 10 mg in the Collaborative Atorvastatin Diabetes Study (CARDS).
Newman CB; Szarek M; Colhoun HM; Betteridge DJ; Durrington PN; Hitman GA; Neil HA; Demicco DA; Auster S; Fuller JH;
Diab Vasc Dis Res; 2008 Sep; 5(3):177-83. PubMed ID: 18777490
[TBL] [Abstract][Full Text] [Related]
6. Statin and the risk of renal-related serious adverse events: Analysis from the IDEAL, TNT, CARDS, ASPEN, SPARCL, and other placebo-controlled trials.
Bangalore S; Fayyad R; Hovingh GK; Laskey R; Vogt L; DeMicco DA; Waters DD;
Am J Cardiol; 2014 Jun; 113(12):2018-20. PubMed ID: 24793673
[TBL] [Abstract][Full Text] [Related]
7. Comparison of benefits and risks of rosuvastatin versus atorvastatin from a meta-analysis of head-to-head randomized controlled trials.
Wlodarczyk J; Sullivan D; Smith M
Am J Cardiol; 2008 Dec; 102(12):1654-62. PubMed ID: 19064019
[TBL] [Abstract][Full Text] [Related]
8. Intensive lipid lowering with atorvastatin in patients with stable coronary disease.
LaRosa JC; Grundy SM; Waters DD; Shear C; Barter P; Fruchart JC; Gotto AM; Greten H; Kastelein JJ; Shepherd J; Wenger NK;
N Engl J Med; 2005 Apr; 352(14):1425-35. PubMed ID: 15755765
[TBL] [Abstract][Full Text] [Related]
9. Safety of high-dose atorvastatin therapy.
Waters DD
Am J Cardiol; 2005 Sep; 96(5A):69F-75F. PubMed ID: 16126026
[TBL] [Abstract][Full Text] [Related]
10. Hepatotoxicity associated with statins: reports of idiosyncratic liver injury post-marketing.
Björnsson E; Jacobsen EI; Kalaitzakis E
J Hepatol; 2012 Feb; 56(2):374-80. PubMed ID: 21889469
[TBL] [Abstract][Full Text] [Related]
11. A placebo-controlled trial examining atorvastatin in dyslipidemic patients undergoing CAPD.
Harris KP; Wheeler DC; Chong CC;
Kidney Int; 2002 Apr; 61(4):1469-74. PubMed ID: 11918754
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular event reduction versus new-onset diabetes during atorvastatin therapy: effect of baseline risk factors for diabetes.
Waters DD; Ho JE; Boekholdt SM; DeMicco DA; Kastelein JJ; Messig M; Breazna A; Pedersen TR
J Am Coll Cardiol; 2013 Jan; 61(2):148-52. PubMed ID: 23219296
[TBL] [Abstract][Full Text] [Related]
13. Severe hepatic injury associated with different statins in patients with chronic liver disease: a nationwide population-based cohort study.
Chang CH; Chang YC; Lee YC; Liu YC; Chuang LM; Lin JW
J Gastroenterol Hepatol; 2015 Jan; 30(1):155-62. PubMed ID: 25041076
[TBL] [Abstract][Full Text] [Related]
14. Effects of atorvastatin on bone in postmenopausal women with dyslipidemia: a double-blind, placebo-controlled, dose-ranging trial.
Bone HG; Kiel DP; Lindsay RS; Lewiecki EM; Bolognese MA; Leary ET; Lowe W; McClung MR
J Clin Endocrinol Metab; 2007 Dec; 92(12):4671-7. PubMed ID: 17726081
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the efficacy and safety of atorvastatin initiated at different starting doses in patients with dyslipidemia.
Jones PH; McKenney JM; Karalis DG; Downey J
Am Heart J; 2005 Jan; 149(1):e1. PubMed ID: 15660024
[TBL] [Abstract][Full Text] [Related]
16. Risk factors for rhabdomyolysis with simvastatin and atorvastatin.
Golomb B; Evans M
Drug Saf; 2006; 29(12):1191; author reply 1191-2. PubMed ID: 17147465
[No Abstract] [Full Text] [Related]
17. Atorvastatin for the treatment of plaque-type psoriasis.
Faghihi T; Radfar M; Mehrabian Z; Ehsani AH; Rezaei Hemami M
Pharmacotherapy; 2011 Nov; 31(11):1045-50. PubMed ID: 22026392
[TBL] [Abstract][Full Text] [Related]
18. Atorvastatin associated liver disease.
Clarke AT; Mills PR
Dig Liver Dis; 2006 Oct; 38(10):772-7. PubMed ID: 16777499
[TBL] [Abstract][Full Text] [Related]
19. An overview of the clinical safety profile of atorvastatin (lipitor), a new HMG-CoA reductase inhibitor.
Black DM; Bakker-Arkema RG; Nawrocki JW
Arch Intern Med; 1998 Mar; 158(6):577-84. PubMed ID: 9521221
[TBL] [Abstract][Full Text] [Related]
20. A comparison of simvastatin and atorvastatin up to maximal recommended doses in a large multicenter randomized clinical trial.
Illingworth DR; Crouse JR; Hunninghake DB; Davidson MH; Escobar ID; Stalenhoef AF; Paragh G; Ma PT; Liu M; Melino MR; O'Grady L; Mercuri M; Mitchel YB;
Curr Med Res Opin; 2001; 17(1):43-50. PubMed ID: 11464446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
